现代消化及介入诊疗
現代消化及介入診療
현대소화급개입진료
MODERN DIGESTION & INTERVENTION
2013年
5期
291-293
,共3页
消化道出血%沙利度胺%小肠%血管发育不良%治疗
消化道齣血%沙利度胺%小腸%血管髮育不良%治療
소화도출혈%사리도알%소장%혈관발육불량%치료
Gastrointestinal hemorrhage%Thalidomide%Small intestinal%Angiodysplasia%Therapy
目的：观察沙利度胺治疗小肠血管发育不良所致消化道出血的临床疗效。方法收集2009年1月～2011年10月小肠血管发育不良所致消化道出血患者20例，给予沙利度胺片100 mg/d口服，疗程4个月，观察治疗前、后患者临床疗效。结果患者临床疗效总评分由治疗前的（14.56±3.30）分降至治疗后的（5.23±3.25）分，差异有统计学意义（P<0.01）。随访期间，20例患者平均出血次数为（1.00±1.13）次，输血量为（100.00±230.01）mL，均比治疗前显著减少[（11.12±5.73）次和（1338.22±1451.32）mL，P值均<0.01]；治疗后血红蛋白含量为（9.41±2.17）g/mL，比治疗前的（5.68±1.60]g/mL）显著上升（P<0.01]。结论沙利度胺对小肠血管发育不良所致的消化道出血疗效显著，可望成为一种治疗小肠血管发育不良的有效药物。
目的：觀察沙利度胺治療小腸血管髮育不良所緻消化道齣血的臨床療效。方法收集2009年1月～2011年10月小腸血管髮育不良所緻消化道齣血患者20例，給予沙利度胺片100 mg/d口服，療程4箇月，觀察治療前、後患者臨床療效。結果患者臨床療效總評分由治療前的（14.56±3.30）分降至治療後的（5.23±3.25）分，差異有統計學意義（P<0.01）。隨訪期間，20例患者平均齣血次數為（1.00±1.13）次，輸血量為（100.00±230.01）mL，均比治療前顯著減少[（11.12±5.73）次和（1338.22±1451.32）mL，P值均<0.01]；治療後血紅蛋白含量為（9.41±2.17）g/mL，比治療前的（5.68±1.60]g/mL）顯著上升（P<0.01]。結論沙利度胺對小腸血管髮育不良所緻的消化道齣血療效顯著，可望成為一種治療小腸血管髮育不良的有效藥物。
목적：관찰사리도알치료소장혈관발육불량소치소화도출혈적림상료효。방법수집2009년1월～2011년10월소장혈관발육불량소치소화도출혈환자20례，급여사리도알편100 mg/d구복，료정4개월，관찰치료전、후환자림상료효。결과환자림상료효총평분유치료전적（14.56±3.30）분강지치료후적（5.23±3.25）분，차이유통계학의의（P<0.01）。수방기간，20례환자평균출혈차수위（1.00±1.13）차，수혈량위（100.00±230.01）mL，균비치료전현저감소[（11.12±5.73）차화（1338.22±1451.32）mL，P치균<0.01]；치료후혈홍단백함량위（9.41±2.17）g/mL，비치료전적（5.68±1.60]g/mL）현저상승（P<0.01]。결론사리도알대소장혈관발육불량소치적소화도출혈료효현저，가망성위일충치료소장혈관발육불량적유효약물。
Objective To observe the therapeutic effect of thalidomide on small intestinal bleeding caused by angiodysplasia. Methods Twenty patients with recurrent small intestinal bleeding caused by an-giodysplasia were treated with thalidomide 100 mg daily for 4 months. Follow-up time was 12 months. The change of clinical setting between pre-therapy and post-therapy was compared. Results The clinical setting of patients in post therapy was significantly better than that in pre-therapy. The overall symptom score, the medi-an bleeding frequency and median transfusion volume in patients after therapy was significantly lower than those before the therapy (14.56 ± 3.30) vs (5.23 ± 3.25), (11.12 ± 5.73) vs (1.00 ± 1.13), (1338.22 ± 1451.32) mL vs (100.00 ± 230.01)mL, respectively, (all P<0.01), while median hemoglobin was obviously higher than that before the therapy(5.68 ± 1.60)g/mL vs (9.41 ± 2.17)g/mL (P<0.01). Conclusions Thalidomide is effec-tive in treating small intestinal bleeding caused by angiodysplasia.
